INTRODUCTIONProstate cancer is the most common non‐cutaneous malignancy and the second leading cause of cancer‐related death in North American men. Patients diagnosed with localized disease are usually treated with surgery or radiotherapy; however, many of these patients are not cured and may later develop a more advanced recurrent form of the disease. Patients with advanced prostate cancer are primarily treated with hormone ablation therapy. While initially most of these patients respond well to treatment, over time the tumor becomes unresponsive and develops into castration‐resistant prostate cancer (CRPC). Current therapies for patients with CRPC, which include taxol‐based chemotherapy, have only temporary effectiveness. Therefore, other treatments that are more effective against advanced prostate cancer and CRPC are needed.Mouse models are essential for expanding our understanding of prostate cancer initiation, development, and progression. In addition, they are vital for the pre‐clincial development of new treatments for advanced prostate cancer. Current mouse models for prostate cancer consist of genetically engineered transgenic mice and mice bearing xenograft tumors. In genetically engineered mice, many genes that are implicated in cancer initiation, development, and progression are altered and modified to create mouse models that mimic cancer progression observed in humans. The advantage of using transgenic mouse
The Prostate – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud